Melanocortin receptor agonist · FDA-approved (HSDD) · Subcutaneous
PT-141 (Bremelanotide): the centrally acting peptide for libido and arousal.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts in the central nervous system to support sexual desire and arousal. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women and is widely used off-label in men for arousal support.
Free shipping over $150 · Pay with card or crypto
What PT-141 (Bremelanotide) is
PT-141 (bremelanotide) is a 7-amino-acid cyclic peptide analogue of alpha-MSH. It was developed from Melanotan II after researchers noticed spontaneous sexual arousal in trial participants — the side effect became the drug.
It is FDA-approved as Vyleesi (AMAG Pharmaceuticals, 2019) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
In men, it is used off-label for arousal and erectile support, particularly in patients who do not fully respond to PDE5 inhibitors (sildenafil, tadalafil) — because PT-141 acts on desire centrally rather than on penile vascular tone.
How it works
PT-141 binds melanocortin receptors — primarily MC4R — in hypothalamic and limbic regions that govern sexual desire and arousal. Effects are CNS-driven, not vascular.
Because the mechanism is central, PT-141 works alongside (not in competition with) PDE5 inhibitors. Patients who do not respond to sildenafil because the issue is desire — not blood flow — often respond to PT-141.
Onset of effect is typically 30–60 minutes after subcutaneous injection; duration ~6–8 hours. It is used on-demand, not daily.
What patients use it for
Improved sexual desire in HSDD
RECONNECT trials (women with HSDD): meaningful improvement in desire score and reduction in distress, with on-demand dosing.
Arousal support in men who do not respond to PDE5 inhibitors
For patients whose primary issue is desire rather than vascular function, PT-141 addresses a complementary mechanism.
On-demand, not daily
No chronic systemic exposure — used only when desired, simplifying side-effect profile and long-term considerations.
Works for both men and women
FDA approval is female-specific (HSDD), but the mechanism is sex-independent and supports off-label male use.
Evidence summary
RECONNECT trials (Kingsberg SA et al., Obstet Gynecol 2019): two pivotal Phase 3 RCTs supporting Vyleesi approval for HSDD in premenopausal women.
Diamond LE et al. (Int J Impot Res, 2004): early Phase 2 work demonstrating bremelanotide efficacy for erectile function in PDE5 non-responders.
Molinoff PB et al. (Ann NY Acad Sci, 2003): pharmacology and CNS mechanism review for the melanocortin pathway in sexual function.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Vyleesi label: 1.75 mg subcutaneously in the abdomen or thigh as needed, at least 45 minutes before anticipated activity. No more than one dose per 24 hours; no more than 8 doses per month.
Off-label compounded protocols for men commonly use 1–2 mg subcutaneously on-demand. Starting at the lower end to assess flushing/nausea is recommended.
Effect typically begins in 30–60 minutes and lasts 6–8 hours.
Safety and contraindications
Most common side effects: nausea (~40%, often dose-related), flushing, headache, injection-site reaction, transient mild blood-pressure elevation.
PT-141 can cause focal hyperpigmentation in some patients, especially with frequent use (related to MC1R cross-activation). Less common at standard on-demand dosing than with daily Melanotan II.
Contraindicated in uncontrolled hypertension or known cardiovascular disease. Vyleesi label specifically warns about transient BP increases — measure baseline BP before initiation.
Pregnancy: not recommended. Reliable contraception during therapy is required by label.
Who it's typically considered for
- Premenopausal women with diagnosed acquired, generalized HSDD (Vyleesi indication)
- Men with arousal-driven (not vascular-driven) sexual dysfunction or partial PDE5 response
- Patients seeking an on-demand option without daily medication
- Patients without uncontrolled hypertension or significant cardiovascular disease
Frequently asked questions
How is PT-141 different from sildenafil (Viagra)?
PT-141 acts centrally on desire and arousal pathways. Sildenafil acts peripherally on penile vasculature. Many patients benefit from one, the other, or both — the mechanisms are complementary.
Can women use PT-141?
Yes — and women are the FDA-approved population (Vyleesi for HSDD). It is the most evidence-supported use case.
How quickly does it work?
Typically 30–60 minutes after injection. Effects last about 6–8 hours. It is intended for on-demand, not daily, use.
Will PT-141 cause skin darkening?
PT-141 has weaker MC1R activity than Melanotan II, but focal hyperpigmentation can occur, especially with very frequent dosing. Used at label frequency (≤8 doses/month), this is uncommon.
Is nausea a problem?
Nausea is the most common side effect and is dose-related. Many patients tolerate a lower starting dose (1.0–1.5 mg) better. Anti-nausea pre-treatment is an option in selected cases.
Can I combine PT-141 with sildenafil or tadalafil?
In selected patients, yes — but combination should be physician-directed because PT-141 transiently elevates blood pressure while PDE5 inhibitors lower it.
Is PT-141 safe with heart conditions?
PT-141 transiently raises blood pressure and is not recommended in uncontrolled hypertension or established cardiovascular disease. Discuss cardiovascular history with your prescriber.
How is PT-141 different from Melanotan II?
Both share melanocortin-receptor activity. PT-141 is more selective for MC4R (sexual function) and weaker at MC1R (pigmentation). Melanotan II drives tanning more strongly; PT-141 drives libido more selectively.
Sources
- Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol (2019). — pubmed.ncbi.nlm.nih.gov/31599840
- FDA prescribing information — Vyleesi (bremelanotide). — www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. J Sex Med (2006). — pubmed.ncbi.nlm.nih.gov/16942538
- Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann NY Acad Sci (2003). — pubmed.ncbi.nlm.nih.gov/12851319
Considering PT-141 (Bremelanotide)?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.